Ustekinumab for treating active psoriatic arthritis

NICE technology appraisal guidance [TA313] Published date:

Ustekinumab (given by itself or with another drug called methotrexate) is not recommended for active psoriatic arthritis when treatment with non-biological disease-modifying antirheumatic drugs (or DMARDs) has not worked well enough.

Ustekinumab should not normally be prescribed on the NHS for active psoriatic arthritis. Your doctor should talk to you about other treatment options available to you.

If you are already taking ustekinumab for active psoriatic arthritis, you should be able to continue taking it until you and your doctor decide it is the right time to stop.

Get involved